Baba Hiromi, Hotta Kenji, Takahashi Ryo, Motegi Kana, Sugama Yuya, Sakae Takeji, Tachibana Hidenobu
Section of Radiation Safety and Quality Assurance, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
Doctoral Program in Biomedical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8577, Japan.
J Radiat Res. 2025 Jan 22;66(1):65-73. doi: 10.1093/jrr/rrae097.
We assessed the effect of beam size on plan robustness for intensity-modulated proton therapy (IMPT) of head and neck cancer (HNC) and compared the plan quality including robustness with that of intensity-modulated radiation therapy (IMRT). IMPT plans were generated for six HNC patients using six beam sizes (air-sigma 3-17 mm at isocenter for a 70-230 MeV) and two optimization methods for planning target volume-based non-robust optimization (NRO) and clinical target volume (CTV)-based robust optimization (RO). Worst-case dosimetric parameters and plan robustness for CTV and organs-at-risk (OARs) were assessed under different scenarios, assuming a ± 1-5 mm setup error and a ± 3% range error. Statistical comparisons of NRO-IMPT, RO-IMPT and IMRT plans were performed. In regard to CTV-D99%, RO-IMPT with smaller beam size was more robust than RO-IMPT with larger beam sizes, whereas NRO-IMPT showed the opposite (P < 0.05). There was no significant difference in the robustness of the CTV-D99% and CTV-D95% between RO-IMPT and IMRT. The worst-case CTV coverage of IMRT (±5 mm/3%) for all patients was 96.0% ± 1.4% (D99%) and 97.9% ± 0.3% (D95%). For four out of six patients, the worst-case CTV-D95% for RO-IMPT (±1-5 mm/3%) were higher than those for IMRT. Compared with IMRT, RO-IMPT with smaller beam sizes achieved lower worst-case doses to OARs. In HNC treatment, utilizing smaller beam sizes in RO-IMPT improves plan robustness compared to larger beam sizes, achieving comparable target robustness and lower worst-case OARs doses compared to IMRT.
我们评估了射野大小对头颈部癌(HNC)调强质子治疗(IMPT)计划稳健性的影响,并将包括稳健性在内的计划质量与调强放射治疗(IMRT)的计划质量进行了比较。使用六种射野大小(等中心处空气等效半径为3 - 17 mm,能量为70 - 230 MeV)以及两种优化方法,为6例HNC患者生成IMPT计划,这两种优化方法分别是基于计划靶体积的非稳健优化(NRO)和基于临床靶体积(CTV)的稳健优化(RO)。在假设存在±1 - 5 mm的摆位误差和±3%的射程误差的不同情况下,评估CTV和危及器官(OARs)的最坏情况剂量学参数及计划稳健性。对NRO-IMPT、RO-IMPT和IMRT计划进行了统计学比较。关于CTV-D99%,射野较小的RO-IMPT比射野较大的RO-IMPT更稳健,而NRO-IMPT则相反(P < 0.05)。RO-IMPT和IMRT之间CTV-D99%和CTV-D95%的稳健性没有显著差异。所有患者IMRT的最坏情况CTV覆盖率(±5 mm/3%)为96.0%±1.4%(D99%)和97.9%±0.3%(D95%)。6例患者中有4例,RO-IMPT(±1 - 5 mm/3%)的最坏情况CTV-D95%高于IMRT。与IMRT相比,射野较小的RO-IMPT对OARs的最坏情况剂量更低。在HNC治疗中,与较大射野相比,在RO-IMPT中使用较小射野可提高计划稳健性,与IMRT相比,可实现相当的靶区稳健性并降低最坏情况OARs剂量。